Recombinant human interleukin-l receptor antagonist (rhIL-l ra) markedly protects against focal ce rebral ischaemia in the rat, implicating endogenous IL-l in the events leading to cerebral infarction, The present experiments investigated the effect of intracerebroven tricular (i.c.v.) administration of IL-113 or rhlL-l ra on ischaemia damage and physiological parameters after per manent middle cerebral artery occlusion in the rat. IL-113 (5 ng, i.c.v.) markedly (92%) enhanced infarct volume and caused a significant rise in body temperature, but rhlL-lra (10 f,1g, i.c. v.) significantly reduced infarct vol ume and did not significantly affect heart rate, blood pres sure, or body temperature. rhIL-l ra administered 30 min Research on the mechanisms underlying neuronal damage caused by cerebral ischaemia has revealed the importance of immune or inflammatory mole cules and cells in the neuronal death that results from stroke. Several recent studies have implicated cytokines such as interleukin-l (IL-l) in experimen tally induced neurodegeneration (Minami et aI.Address correspondence and reprint requests to Prof. N.
before, or at the time of ischaemia significantly reduced infarct volume in cortex (55 and 60%, respectively) and striatum (52 and 41%, respectively). rhlL-l ra adminis tered 30 min after ischaemia significantly reduced total and cortical infarct volume (26 and 29%, respectively), but did not significantly protect striatal tissue. The effects of rhlL-l ra were still evident in both cortex and striatum 7 days after ischaemia. These results support the role of IL-l in ischaemic brain damage, revealing potent, sus tained, neuroprotective effects of rhlL-lra in the cortex and striatum, which cannot be attributed directly to changes in physiological parameters. Key Words: Inter leukin-l receptor antagonist-Cerebral ischaemia-Rat.
(IL-l a and IL-l (3) and the endogenous receptor an tagonist (rhIL-lra) are synthesised in the brain (Breder et aI., 1988; Lechan et aI., 1990; Licinio et aI., 1991) . Constitutive expression of IL-I in normal brain is low, but IL-l f3 mRN A is induced rapidly after experimentally induced cerebral ischaemia in the rat (Minami et aI., 1992a; Liu et aI., 1993; But tini et aI., 1994; Yabuuchi et aI., 1994; Wang et aI., 1995) , and increased expression of the protein has been reported after brain injury in rodents and hu mans (McClain et aI., 1987; W oodroofe et aI., 1991; Yan et aI., 1992; Taupin et aI., 1993) . IL-l exerts diverse actions in the brain on both neuronal and glial function, some of which have potentially ben eficial effects on neuronal survival after brain in sults (Giulian et aI., 1988; Miller et aI., 1990; Spranger et aI., 1990; Plato-Salaman and Ffrench Mullen, 1992) . However, we have proposed that brain IL-l participates directly in ischaemic and traumatic brain injury. This hypothesis is based on our observation that intracerebroventricular (i.e. v.) administration of rhIL-lra markedly (>50%) inhib-its neuronal damage induced by focal cerebral isch aemia (middle cerebral artery occlusion) (Relton and Rothwell, 1992) or fluid percussion injury in the rat (Toulmond and Rothwell, \995) .
These data suggest that endogenous IL-\ medi ates ischaemic brain damage, and are supported by the observations of Minami et al. (I992h) and Ya masaki et al. (1992, 1995) , who reported that intra cerebroventricular (i.c. v.) administration of IL-I � significantly exacerbates neuronal loss after global ischaemia in the gerbil, and oedema after temporary focal ischaemia. However, IL-I is a potent pyro gen, and because these forms of damage are highly susceptible to even modest changes in body tem perature, the data may reflect an indirect effect of IL-I on neuronal survival. Thus, it is important to quantify the effect of IL-I and rhIL-1 ra on body temperature and other physiological parameters be cause these might influence ischaemic damage. The potent effects of rhIL-\ ra on neurodegeneration im ply that pharmacological manipUlation of IL-\ syn thesis or action may be beneficial in the treatment of stroke. The time course of action of rhIL-1 ra and effects on specific brain regions are important con siderations in assessing therapeutic value of this and related treatments (Hunter et aI., 1995) .
The objectives of the present study were to in vestigate in more detail effects of IL-I and rhIL-1 ra on neuronal damage induced by focal cerebral isch aemia [middle cerebral artery occlusion (MCAo)] in the rat, to analyse the impact of these treatments on body temperature, and to investigate the time course and tissue distribution of the neuroprotec tive actions of rhlL-1 ra.
MATERIALS AND METHODS
All experiments were performed on male, Sprague Dawley rats (Charles River, UK), weighing 230-270 g.
Animals were housed at 21°C with free access to food and water.
Surgical procedures
Guide cannulae were stereotaxically implanted into the lateral ventricle of the brain of rats under sodium pento barbitone anaesthesia (60 mg/kg) 7 days before induction of ischaemia to permit administration of substances into the brain. At this time, radiotransmitters (Data Sciences, U.S.A.) were also implanted into the peritoneum, to al low subsequent recording of body temperature by remote radiotelemetry in conscious animals.
Cerebral ischaemia was induced by permanent unilat eral occlusion of the middle cerebral artery, using an ad aptation (Bederson et aI., I 986h) of the method described by Tamura et al. (I98\) . Anaesthesia was induced by in halation of 4% halothane in oxygen, and maintained by 2-3% halothane throughout surgery. A 2-cm incision was made midway between the lateral margin of the left orbit and the auditory canal. The temporalis muscle was ele-vated to expose the subtemporal fossa, and a craniotomy was made using a dental drill. The dura was pierced and the left MCA was exposed and occluded proximally be low the lenticulostriate branch, and again, at the level of the inferior cerebral vein, using a bipolar coagulator (Downs Surgical, UK). The artery was then cut between these two points to prevent recannalisation. After sur gery, soft tissues were replaced and the wound was stitched. Animals were maintained on a heated mat until they regained consciousness.
Temperature recording
Body temperature was recorded in conscious, free moving animals by remote radiotelemetry at an ambient temperature of 21°C, immediately after recovery from surgery. To avoid the complication of circadian variation, body temperature was recorded, for 24 h before and the 24 h after MCAo to allow calculation of the change in body temperature due to ischaemia. Data are therefore presented as the difference in temperature after ischaemia relative to the previous day shown at 30-min intervals.
Blood pressure and heart rate recordings
In separate groups of rats, maintained under halothane anaesthesia, mean arterial blood pressure and heart rate were measured by pressure transduction and arterial pulse, respectively, via an indwelling cannula inserted in the left femoral artery. Parameters were measured for 30 min before MCAo to obtain baseline levels, then for 45 min after MCAo. Data are presented as change from mean baseline values.
Measurement of infarct size
In most experiments, delineation of the lesion was de termined on fresh tissue. Sequential, 500-fLm coronal brain sections were incubated in 2% triphenyl tetrazolium chloride (TTC; Sigma Chemical Co., UK), a stain for mitochondrial viability, until a clear delineation of brain infarction could be observed. The lesion area was charted onto stereotaxic maps (thus correcting for any swelling due to brain oedema), and subsequently measured by au tomated SeeScan image analysis. Lesion volume was cal culated by integration of the areas of infarct for each an imal.
For more detailed histological analysis, or analysis at time points later than 24 h, brains were frozen in isopen tane at -30°C, and stored at -70°C. Coronal sections, 15 fLm each, were cut on a cryostat at -21°C at 500-fLm intervals through the whole brain. Sections were thaw mounted onto chromium-gelatin-coated microscope slides, dried, and stored at -70°C before staining with haematoxylin and eosin for light microscopic analysis.
Infarct volume was calculated as already described. All analysis was performed "blind."
Experimental procedures
In the first study, effects of i.c. v. injection of human recombinant IL-I [3 (rhIL-1 [3, Dupont, U.S.A., specific activity 200 IU/ng, endotoxin content 2.5 EUlmg protein) on ischaemic damage and core temperature after MCAo was investigated. IL-I � (2.5 ng in 4 fLl) was infused (over of fever (Rothwell and Hopkins, 1995) . Control animals were infused with an appropriate volume of sterile, 0.9% saline. Body temperature was recorded for 24 h before and 24 h after MCAo by radiotelemetry. Ischaemic dam age was assessed 24 h after MCAo by TTC staining.
In a separate experiment, the effects of i.c. v. injection of rhIL-ira on ischaemic brain damage was compared with that of the noncompetitive N-methyl-o-aspartate (NMDA) receptor antagonist, MK-80I. An optimum dose (10 /-lg in 4 /-ll) of rhIL-ira (donated by Synergen, U.S.A.) or vehicle (4 /-ll, sterile saline) was infused into the right lateral cerebral ventricle (as already described) 30 min before and 10 min after induction of ischaemia (total dose 20 /-lg). MK-80I (4 mg/kg, dizocilpine maleate, MSD, U.K.) or vehicle was administered intraperitoneally 30 min before MCAo. Damage was assessed 24 h after MCAo by TTC staining.
To investigate the possibility that rhIL-ira protects against ischaemic damage by modifying physiological pa rameters, core temperature, blood pressure, and heart rate were measured in animals subjected to MCAo and treated with rhIL-ira or saline (administered as described in the second experiment).
The time course of action of rhIL-ira was assessed in separate groups of animals injected i.c. v. with a single dose of 10 /-lg rhIL-l ra or vehicle either 30 min before ( -30 min), at the time of ischaemia (0 min), or 30 min after MCAo (+ 30 min). Animals were killed 24 h after MCAo, and damage was assessed by TTC staining. To determine whether the neuroprotective effects of rhIL Ira were sustained, rhIL-ira (10 /-lg) or vehicle was in fused at the time of MCAo (0 h), and groups of animals were killed either I or 7 days after MCAo. These brains were frozen and subsequently stained using haematoxylin and eosin for analysis by light microscopy.
Statistical analysis
All data are expressed as mean ± standard deviation. The number of animals in each group are presented in the figure legends (see following section). Statistical differ ences between lesion volume were assessed using the Students' unpaired t test. Temperature, blood pressure, and heart rate data were analysed by multiple analysis of variance. Probabilities are two-tailed, assuming a proba bility of <5% for statistical significance.
RESULTS
All animals subjected to MCAo sustained focal brain damage throughout the left cortex and basal ganglia when observed 24 h after surgery. An ex ample of the typical distribution of damage as ob served in control animals is shown in Fig. lA . Dam age was always seen in the frontal cortex and lateral striatum, and usually in the sensorimotor and audi tory areas of the cortex, and the medial area of the striatum. Very low mortality «5%) was associated with surgery and injection of either vehicle, rhIL Ira or IL-l�, and no neuronal damage was observed in sham-operated rats (artery exposed, but not oc cluded-data not shown). All animals that under went MCAo demonstrated splaying of the contra- 16, No. 5, 1996 lateral extremities, and circling; some animals also exhibited "barrel rolling" (ipsilateral turning).
Experiment 1
Central administration of IL-l� (2. 5 ng, i. c. v. , 30 min and 2 h after MCAo) caused a marked exacer bation of ischaemic damage at all brain levels ( Fig.  2A) , resulting in a large (92%), and statistically sig nificant (p < 0.001) enhancement of lesion volume, compared with animals injected with vehicle. The effect of infusion IL-l � or vehicle on body temper ature after MCAo is shown in Fig. 2B . Basal (pre surgery) temperatures were similar in groups in jected with saline (37. 3 ± O.loC, n = 7) or IL-l� (37. 4 ± 0.2°C, n = 6). Treatment with IL-I� re sulted in a rapid increase in core temperature, which began soon after recovery from anaesthesia, and reached a maximal value, of � 38.9°C, between 3 and 4 h later. This increase in temperature was significantly greater (1. 5°C, p < 0. 001) than that of vehicle-treated animals. Body temperature had re turned to presurgery levels by 8 h after ischaemia. In saline-injected rats, core temperature returned to values similar to those recorded on the previous day within 2 h after surgery, and thereafter remained relatively constant.
Experiment 2
The data presented in Fig. 3 demonstrate that in jection of rhIL-lra (i. c.v.) or MK-80l (i. p.) signifi cantly reduced, by a similar extent, infarct volume measured 24 h after MCAo. Peripheral administra tion of MK-80l (4 mg/kg, i. p. , 30 min before MCAo) caused a marked (67%) and statistically significant (p < 0. 01) reduction in lesion volume (vehicle 85. 8 ± 45.0 mm 3 , n = 8, MK-801 27. 9 ± 7. 0 mm 3 ). This reduction in damage was evident through all levels of the brain. Central administration of rhIL-I ra (10 /-lg, i.c.v., 30 min before and to min after MCAo) also resulted in a marked (72%) and statistically sig nificant (p < 0.01) reduction in lesion volume (con tro199. 1 ± 43. 4, n = 7, rhIL-lra 27.8 ± 7. 8, n = 8). The residual volume of damage was remarkably sim ilar in animals treated with rhIL-lra (27.8 mm 3 ) or MK-801 (27. 8 mm 3 ).
Experiment 3
Changes in heart rate, and mean arterial blood pressure over the 45 min after MCAo are presented in Table I . Resting heart rate and mean arterial blood pressure were similar and stable in all animals before surgery (320 ± 16 beats/min and 89 ± 3 mm Hg, respectively). Central injection (10 /-lg, i. c. v. ) of rhIL-I ra 30 min before surgery had no significant effect on either parameter. In vehicle-treated rats, MCAo caused modest and transient increases in blood pressure (29%) and heart rate (13%), which were maximal 20 min after surgery. rhIL-lra slightly, but not significantly attenuated these changes (Table I) . Blood pressure and heart rate were monitored for longer periods (up to 2 h) in a small number of animals, but no differences be tween vehicle-or rhIL-I ra-treated animals were ob servl�d. Changes in body temperature observed during the 24 h after MCAo are presented in Table 2 . Basal body temperatures were similar in MCAo rats treated with saline (37.2 ± 0.2°C, n = 7) or rhIL-lra (37.4 ± 0.3°C, n = 8). After an initial, transient hypothermia (�1 °C), presumably due to the affects of anaesthesia, body temperature remained stable in animals treated with rhIL-I ra, which had no sta tistically significant effect on the change in temper ature observed after MCAo.
Experiment 4
Results presented in Fig. 4 illustrate the effect of delayed treatment with rhIL-I ra on infarct volume caused by MCAo. Pretreatment with rhIL-lra (10 jJ-g, i.c. v.) 30 min before MCAo resulted in a marked and significant reduction of ischaemic dam age throughout both cortex (54.9 ± 6.3%, p < 0.001) and striatum (52.1 ±7 .7%,p<0.00l,n = 7). A typical example of the distribution of damage seen after this treatment is shown in Fig. 2B . A single injection of rhlL-lra (10 jJ-g, i.c.v.) at the time of MCAo inhibited cortical damage to a similar ex tent (59.7 ± 3.3%, p < 0.001), but caused a slightly reduced level of striatal protection (41.1 ± 6.8%, p < 0.001, n = 8). When administration of rhIL-lra was delayed until 30 min after MCAo, a smaller but nonetheless significant inhibition (28.8 ± 9.7%, n = J Cereb Blood Flow Metab, Vol. 16. No.5. 1996 13) of cortical damage was observed, but no striatal protection was evident.
Data shown in Fig. 5 illustrate that protection with rhIL-lra (10 j.Lg, i.c.v., 0 h) is still apparent 7 days after ischaemia. The inhibition of infarct vol ume measured 7 days after MeAo was similar to that observed at 24 h, throughout both the cortex (55.3 ± 5.3%) and striatum (36.7 ± 7.6%), and in both regions infarct volume was significantly lower than that of vehicle-treated rats, p < 0.001 for cor tical and p < 0.01 for striatal damage.
DISCUSSION
The results of these studies confirm and extend our previous findings, and show that rhIL-lra is a potent inhibitor of experimentally induced isch aemic brain damage. In seven separate experiments we have observed inhibition of ischaemic brain damage in the rat by rhIL-lra of up to 78%. A sim ilar neuroprotective effect of rhIL-lra has now been observed in focal ischaemia in the mouse (N. J. Rothwell, L. Rothwell, and C. Davies, unpublished data) , traumatic brain damage in the rat (Toulmond and Rothwell, 1995) and perinatal hypoxic brain damage in the rat (Martin et aI., 1995) .
A number of studies have reported increased ex pression of IL-l mRNA or protein after experimen tal ischaemic, traumatic, or excitotoxic brain dam age (e.g., McClain et aI., 1987; Minami et aI., 1990; W oodroofe et aI., 1991; Minami et aI., 1992a; Yan et aI., 1992; Liu et aI., 1993; Taupin et aI., 1993; Buttini et aI., 1994; Yabuuchi et aI., 1994; Wang et aI., 1995) . These observations implicate IL-l in the processes of neuronal death and/or repair and re covery. Experiments on cultured neurons in vitro have revealed that IL-l protects cultured neurons Data are presented as change in BP or HR from mean values recorded over 30 min prior to MCAo in animals treated with either saline (n = 6) or rhIL-lra (n = 6, 10 fLg, icv, 30 min before MCAo). 
Data are presented as change in Tc, from mean values re corded over 24 h prior to MCAo, in animals treated with either saline (n = 6) or rhIL-Ira (n = 6, 10 fLg, icv, 30 min before MCAo).
from excitotoxic insults (Strijbos and Rothwell, 1995) and this, together with the fact that IL-l in duces expression of nerve growth factor (Gadient et aI., 1990; Spranger et aI., 1990) , implies that IL-1 acts to limit neurodegeneration. However, the re sults of the present study are not consistent with this hypothesis. i.c.v. injection of IL-If3 massively exacerbated neuronal damage caused by MCAo, but did not cause measurable neuronal damage when infused i.c. v. or into brain tissue in normal rats (data not shown). It is diffiwlt to equate the dose of IL-I f3 injected (5 ng, i.e., < 1 pmol) with brain concentrations after ischaemia, and the quan tity administered may have been supramaximal, al though this dose is optimal for induction of several other responses to IL-I such as fever, behavioural changes, and hypothalamus pituitary adrenal acti-
Omin +30min Timing of rhlL-1 ra/vehicle administration vation (Rothwell and Hopkins, 1995) . Nevertheless, these results are not consistent with protective ac tions of IL-I. The mechanisms by which exogenous IL-I exacerbates ischaemic damage are unknown, but may relate to its effect on body temperature (Fig. 2B ). IL-I exacerbates brain damage caused by global ischaemia in the gerbil (Minami et aI., 1992b) and reperfusion injury in the rat (Yamasaki et aI., 1992 (Yamasaki et aI., , 1995 , but these forms of damage are highly susceptible to changes in body temperature (Gins berg et aI., 1992; Ridenour et aI., 1992) . Damage resulting from focal ischaemia (MCAo) is consider ably less sensitive to hyperthermia (Ridenour et aI., 1992; Morikawa et aI., 1992) , although the extent of fever (> ISC) is likely to have exerted some influ ence on neuronal variability. In an attempt to de termine the contribution of the raised body temper ature to the exacerbation of ischaemic damage, ex periments to block the pyrogenic response to IL-I f3 were considered. However, treatments that effec tively block IL-lf3 fever (e.g., glucocorticoids, cy cloxygenase inhibitors, corticotrophin-releasing factor antagonist, lipocortin, etc.) all affect directly ischaemic damage due to MCAo, independently of effects on body temperature. rhIL-\ ra can also in hibit the pyrogenic effects of IL-I f3, but because of its potent effects on MCAo, experiments to test whether rhIL-lra inhibits the potentiation of dam age by IL-\ f3 would be difficult to interpret. How ever, i.c.v. injection of IL-6 at a dose (50 ng) that causes comparable fever inhibited rather than en hanced ischaemic damage (S. A. Loddick and N. 1. Rothwell, unpublished data) , indicating that fever is not the primary reason why IL-I increases isch aemic damage.
Experiments using rhlL-lra provide more com pelling evidence that endogenous IL-I mediates ischaemic brain damage. After testing a range of doses (I-50 j.Lg, i.c.v., data not shown), lO j.Lg rhIL Ira was found to cause maximal inhibition of dam age, and was used in all subsequent experiments. The rate of diffusion of rhIL-lra into the brain from CSF and its half-life in the CNS are not known ac curately, although our preliminary data indicate a half-life of �60 min after i.c.v. injection in the rat (X. Luheshi, X. Miller, X. Poole, and N. 1. Roth well, unpublished data). Thus, sustained infusion or overexpression of rhIL-lra may have caused greater protection.
Damage caused by permanent occlusion of the MCA was reproducibly observed in areas of the cortex and striatum, consistent with the original studies describing this protocol (Tamura et aI., 1981; Bederson et aI., 1986b) . Tetrazolium chloride staining was employed to assess neuronal damage in all acute (up to 24 h) studies, because it enables infarct size to be rapidly calculated. This method is now used widely to assess ischaemic damage, and has been favourably compared with the more tradi tional method of haematoxylin and eosin staining (Bederson et aI., 1986a; Lin et aI., 1993) , and in the present study almost identical patterns of damage and effects of rhIL-l ra were observed using tetra zolium or haematoxylin and eosin to assess damage at 24 h (data not shown). In addition, an almost identical pattern of protection from rhIL-lra was observed when damage was assessed 7 days after MCAo, indicating that rhlL-lra did not simply de lay neurodegeneration (Fig. 5) .
rhIL-lra is a selective, competitive receptor an tagonist at the IL-l receptor (Dinarello and Thomp son, 1991) that is present in normal brain (Licinio et aI., 1991) , and as yet no actions other than inhibi tion of lL-l receptors have been demonstrated. The protective effects of rhIL-lra were comparable to that of the noncompetitive NMDA receptor antag onist, MK-801 (Fig. 2) , and the residual damage seen after injection of rhIL-lra or MK-801 was al most equal. Neuroprotective effects of MK-801 have been studied extensively in several forms of neurodegeneration including focal ischaemia (Al bers et aI., 1989 (Al bers et aI., , 1992 , but behavioural side effects mean that it is unlikely to have a clinical application (Olney et aI., 1989; Muir and Lees, 1995) .
rhIL-lra did not significantly affect body (perito- Vol. 16, No.5, 1996 neal) temperature, mean arterial blood pressure, or heart rate in sham-operated or MCAo rats (Tables I  and 2 ). The possibility that rhIL-lra affected brain temperature independently of core temperature cannot be excluded, although this seems unlikely as a primary mechanism of action, The modest effect of rhIL-l ra on the small rise in blood pressure after MCAo may reflect an indirect action due to the marked reduction in brain damage in rhIL-I ra treated animals. These data suggest that rhIL-lra protects against cerebral ischaemia by modifying the neurochemical events leading to neuronal death, rather than affecting physiological parame ters. This proposal is supported by our observations that rhlL-lra also markedly inhibits neuronal dam age induced by pharmacological overactivation of NMDA or AMPA receptors in vivo (Relton and Rothwell, 1992; Lawrence and Rothwell, 1994) . The marked inhibition of ischaemic damage by rhIL-lra reflected protection against striatal as well as cortical damage ( Fig. IB and Fig. 3 ). Relatively few agents have been reported to limit striatal dam age after MCAo (Muir and Lees, 1995) , because this is the primary area of infarct after occlusion of the MCA (Shigeno et aI., 1985; Garcia et aI., 1995) . rhIL-I ra also inhibited damage to a similar extent in both brain regions when administered at the time of ischaemia. However, delayed injection of rhlL-lra (30 min after MCAo) protected cortical but not stri atal tissue, presumably due to the earlier progres sion of damage in the striatum. Because rhlL-l ra may diffuse slowly from the ventricles into brain tissue (particularly when blood flow is reduced), it is likely that direct application of rhlL-l ra to the site of brain damage may be effective some time after the ischaemic event.
The mechanism of these neuroprotective effects of rhlL-lra are unknown. Several hypotheses to ex plain the actions of rhlL-I ra or IL-I have been de scribed (Relton and Rothwell, 1992) , which include modification of oedema, blood-brain barrier dam age, release of arachidonic acid or its products, or corticotropin-releasing factor and nitric oxide syn thesis. The magnitude of inhibition of damage by rhlL-lra and its effects on excitotoxic, ischaemic, and traumatic brain damage suggest either a site of action common to diverse forms of insult, or effects at mUltiple points in the cascade of neurodegenera tion.
rhlL-lra is a large protein, and therefore does not cross the blood-brain barrier readily. However, neuroprotective effects of systemically injected rhlL-lra have been reported (Relton et aI., 1993) . Overall, these data indicate that pharmacological strategies to inhibit the synthesis or actions of brain IL-l may offer considerable benefit ill ischaemic and related forms of degeneration.
